Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)

(2013) Krzysztof Zak et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Autophagy in Human Health and Disease

(2013) Augustine M.K. Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural insights into the dual-targeting mechanism of Nutlin-3

(2012) Jae-Sun Shin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

(2012) S. Surget et al.   CANCER RESEARCH

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma

(2012) Kenneth C. Anderson   JOURNAL OF CLINICAL ONCOLOGY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

(2012) S Z Usmani et al.   LEUKEMIA

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

(2011) R. J. Jones et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Molecular Mimicry-Based Repositioning of Nutlin-3 to Anti-Apoptotic Bcl-2 Family Proteins

(2011) Ji-Hyang Ha et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

(2010) B. A. Walker et al.   BLOOD

Multiple myeloma: biology of the disease

(2010) Anuj Mahindra et al.   BLOOD REVIEWS

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

(2010) Flavia Pichiorri et al.   CANCER CELL

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase

(2010) You-Tong Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

(2010) Bart Barlogie et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains

(2010) Hong Chang et al.   LEUKEMIA RESEARCH

Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma

(2010) L Yang et al.   ONCOGENE

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

(2009) M. G. Ooi et al.   CLINICAL CANCER RESEARCH

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010

(2009) H. Brenner et al.   HAEMATOLOGICA

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

(2008) W. Xiong et al.   BLOOD

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Regulation of autophagy by cytoplasmic p53

(2008) Ezgi Tasdemir et al.   NATURE CELL BIOLOGY

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA